Patents by Inventor William LaRochelle

William LaRochelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies directed to GPNMB and uses thereof
    Patent number: 8846873
    Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: September 30, 2014
    Assignees: Celldex Therapeutics, Inc., Amgen Fremont, Inc.
    Inventors: Feng Xiao, Xiao-Chi Jia, Meina Liang, Orit Foord, Scott Klakamp, Kam Fai Tse, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael Jeffers, William LaRochelle, Gulshan Ara, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
  • ANTIBODIES DIRECTED TO GPNMB AND USES THEREOF
    Publication number: 20130244255
    Abstract: The present invention relates to antibodies with specificity to GPNMB, and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides biomarkers for evaluating the effects of therapeutic methods and uses of the antibodies with specificity to GPNMB.
    Type: Application
    Filed: February 7, 2012
    Publication date: September 19, 2013
    Inventors: Vincent A. Pollack, William LaRochelle
  • Compositions Using Antibodies Directed To GPNMB And Uses Thereof
    Publication number: 20130156784
    Abstract: The present invention relates to antibodies, including fully human monoclonal antibodies, with specificity to GPNMB, and uses of such antibodies. The present invention further provides compositions that increase expression of GPNMB on the surface of tumor cells, and methods of using such compositions to increase the anti-cancer activity or other therapeutic efficacy of the antibodies and immunoconjugates provided herein.
    Type: Application
    Filed: July 9, 2012
    Publication date: June 20, 2013
    Inventors: Michael Jeffers, William LaRochelle
  • Antibodies Directed To GPNMB And Uses Thereof
    Publication number: 20130022597
    Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
    Type: Application
    Filed: January 20, 2012
    Publication date: January 24, 2013
    Inventors: Meina Liang, Orit Foord, Scott Klakamp, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael Jeffers, William LaRochelle, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
  • Antibodies against the tenascin major antigens
    Publication number: 20070098715
    Abstract: The invention described herein relates to antibodies directed to the antigen Ten-M2 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen Ten-M2. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Application
    Filed: March 27, 2006
    Publication date: May 3, 2007
    Inventors: Seth Ettenberg, Stephanie Masterman, William LaRochelle, Haihong Zhong
  • Novel proteins and nucleic acids encoding same
    Publication number: 20060234255
    Abstract: The present invention provides novel isolated polynucleotides and small molecule target proteins encoded by the polynucleotides. Antibodies that immunospecifically bind to a novel small molecule target protein or any derivative, variant, mutant or fragment of that protein, polynucleotide or antibody are disclosed, as are methods in which the small molecule target protein, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Application
    Filed: January 26, 2006
    Publication date: October 19, 2006
    Inventors: Carol Pena, Li Li, Steven Spaderna, William LaRochelle, Kerry Quinn-Senger, Mario Leite
  • Novel proteins and nucleic acids encoding same
    Publication number: 20060211031
    Abstract: The present invention provides novel isolated polynucleotides and small molecule target polypeptides encoded by the polynucleotides. Antibodies that immunospecifically bind to a novel small molecule target polypeptide or any derivative, variant, mutant or fragment of that polypeptide, polynucleotide or antibody are disclosed, as are methods in which the small molecule target polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Application
    Filed: April 6, 2006
    Publication date: September 21, 2006
    Inventors: Haihong Zhong, William LaRochelle, Suresh Shenoy, Nikolai Khramtsov
  • Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
    Publication number: 20060210559
    Abstract: Disclosed herein are nucleic acid sequences that encode polypeptides. Also disclosed are antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids, polypeptides, or antibodies, or fragments thereof.
    Type: Application
    Filed: March 20, 2006
    Publication date: September 21, 2006
    Inventors: William LaRochelle, Suresh Shenoy, Mohan Dhanabal, Nikolai Khramtsov, Craig Hackett
  • Treatment of inflammatory bowel disease using growth factors
    Publication number: 20060094647
    Abstract: The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotide sequences and the FGF-CX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.
    Type: Application
    Filed: November 6, 2001
    Publication date: May 4, 2006
    Inventors: Michael Jeffers, Richard Shimkets, Sudhirdas Prayaga, Ferenc Boldog, Meijia Yang, Catherine Burgess, Elma Fernandes, Beth Rittman, Juliette Shimkets, William LaRochelle, Henri Lichenstein
  • Novel proteins and nucleic acids encoding same
    Publication number: 20060084054
    Abstract: The present invention provides novel isolated polynucleotides and small molecule target polypeptides encoded by the polynucleotides. Antibodies that immunospecifically bind to a novel small molecule target polypeptide or any derivative, variant, mutant or fragment of that polypeptide, polynucleotide or antibody are disclosed, as are methods in which the small molecule target polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Application
    Filed: June 4, 2003
    Publication date: April 20, 2006
    Inventors: John Alsobrook, David Anderson, Jason Baumgartner, Constance Berghs, Ferenc Boldog, Catherine Burgess, Stacie Casman, Elina Catterton, Mohanraj Dhanabal, Shlomit Edinger, Karen Ellerman, Seth Ettenberg, Esha Gangolli, Valerie Gerlach, Linda Gorman, William Grosse, Erik Gunther, Xiaojia Guo, Vladimir Gusev, John Herrmann, Weizhen Ji, Ramesh Kekuda, Nikolai Khramtsov, William LaRochelle, Li Li, Hongping Liang, Kenneth Low, John MacDougall, Timothy Maclachlan, Uriel Malyankar, Kelly McQueeney, Amanda Mezick, Charles Miller, Isabelle Millet, Muralidhara Padigaru, Meera Patturajan, John Peyman, Xiaozhong Qian, Luca Rastelli, Daniel Rieger, Mark Rothenberg, Suresh Shenoy, Richard Shimkets, Glennda Smithson, Kimberly Spytek, David Stone, Sujatha Sukumaran, Edward Szekeres, Corine Vernet, Edward Voss, Adam Wolenc, Mei Zhong, Haihong Zhong
  • Methods of preventing and treating alimentary mucositis
    Publication number: 20050256042
    Abstract: The present invention relates to compositions and methods for preventing and treating alimentary mucositis. More particularly, the present invention provides methods for preventing and/or treating alimetary mucositis by using compositions comprising FGF-20, a fragment, a derivative, a variant, a homolog, or an analog thereof.
    Type: Application
    Filed: November 3, 2004
    Publication date: November 17, 2005
    Inventors: Michael Jeffers, Zachary Yim, Pascal Valax, Pradyumna Namdev, Rajeev Chillakuru, William LaRochelle, Henri Lichenstein, Enrique Alvarez, William Hahne
  • Novel fibroblast growth factors and methods of use thereof
    Publication number: 20050256039
    Abstract: The present invention relates to compositions and methods of treatment of various conditions, including but are not limited to, stroke, wound healing, and joint diseases (e.g., osteoarthritis and rheumatoid arthritis). More particularly, the present invention relates to compositions comprising a member of the fibroblast growth factor family, FGF-CX (also known as CG53135-05 or FGF-20), its related polypeptides, nucleic acids encoding such polypeptides, and their uses for treating a condition, such as but is not limited to, stroke, would healing, and joint diseases (e.g., osteoarthritis and rheumatoid arthritis).
    Type: Application
    Filed: May 10, 2004
    Publication date: November 17, 2005
    Inventors: Jeffery Peterson, Paul Sciore, Peter Mezes, Henri Lichenstein, Michael Jeffers, William LaRochelle, Marie Ruiz-Martinez, Galina Chernaya
  • Novel fibroblast growth factor and nucleic acids encoding dame
    Publication number: 20050208514
    Abstract: The present invention generally relates to nucleic acids, proteins, and antibodies. The invention relates more particularly to nucleic acid molecules, proteins, and antibodies of Fibroblast Growth Factor-20 (FGF-20), or its fragments, derivatives, variants, homologs, analogs, or a combination thereof.
    Type: Application
    Filed: November 3, 2004
    Publication date: September 22, 2005
    Inventors: John Alsobrook, Ferenc Boldog, Michael Jeffers, William LaRochelle, Denise Lepley, Henri Lichenstein, Richard Shimkets, Meijia Yang, Marie Ruiz-Martinez, Galina Chernaya, Muralidhara Padigaru, Sudhirdas Prayaga, Mei Zhong
  • Novel polynucleotides and proteins encoded thereby
    Publication number: 20050191681
    Abstract: The present invention provides novel isolated SECX polynucleotides and the membrane-associated or secreted polypeptides encoded by the SECX polynucleotides. Also provided are the antibodies that immunospecifically bind to a SECX polypeptide or any derivative, variant, mutant or fragment of the SECX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the SECX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
    Type: Application
    Filed: February 14, 2005
    Publication date: September 1, 2005
    Applicant: CuraGen Corporation
    Inventors: Richard Shimkets, William LaRochelle
  • Methods of preventing and treating inflammatory bowel disease
    Publication number: 20050164929
    Abstract: The present invention relates to compositions and methods for preventing and treating an inflammatory disorder of a mucosa, including but is not limited to, inflammatory bowel disease and irritable bowel syndrome. More particularly, the present invention relates to compositions comprising FGF-20, a fragment, a derivative, a variant, a homolog, or an analog thereof, and their uses in preventing and treating an inflammatory disorder of a mucosa, such as inflammatory bowel disease or irritable bowel syndrome.
    Type: Application
    Filed: November 3, 2004
    Publication date: July 28, 2005
    Applicant: LUPINE LOGIC, INC.
    Inventors: Enrique Alvarez, Jeffrey Peterson, William LaRochelle, Henri Lichenstein, Michael Jeffers
  • Antibodies against secretoryleukocyte protease inhibitor
    Publication number: 20050142137
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against secretory leukocyte protease inhibitor (SLPI) and antigen binding fragments thereof. Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules are provided. The invention provides antibodies and antigen-binding fragments thereof specifically bind to SLPI; act to neutralize SLPI activity; and can modulate SLPI effects.
    Type: Application
    Filed: November 8, 2004
    Publication date: June 30, 2005
    Applicant: CuraGen Corporation
    Inventors: Michael Gallo, Daniel Chui, Haihong Zhong, Gulshan Ara, William LaRochelle
  • Antibodies to fibroblast growth factor and their methods of use
    Publication number: 20050063971
    Abstract: The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-CX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as other uses.
    Type: Application
    Filed: September 23, 2004
    Publication date: March 24, 2005
    Inventors: Michael Jeffers, Richard Shimkets, Sudhirdas Prayaga, Ferenc Boldog, Meijia Yang, Catherine Burgess, Elma Fernandes, John Herrmann, William LaRochelle, Henri Lichenstein
  • Therapeutic polypeptides, nucleic acids encoding same, and methods of use
    Publication number: 20040029150
    Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Application
    Filed: March 31, 2003
    Publication date: February 12, 2004
    Inventors: John Alsobrook, David Anderson, Ferenc Boldog, Catherine Burgess, Stacie Casman, Shlomit R. Edinger, Valerie Gerlach, William Grosse, Xiaojia Guo, Vladimir Gusev, Weizhen Ji, William LaRochelle, Denise Lepley, Li Li, Xiaohong Liu, John R. MacDougall, Uriel M. Malyankar, Isabelle Millet, Muralidhara Padigaru, Meera Patturajan, John A. Peyman, Luca Rastelli, Daniel Rieger, Mark E. Rothenberg, Richard Shimkets, David J. Stone, Raymond Taupier, Corine Vernet, Bryan Zerhusen
  • Attenuated and dominant negative variant cDNAs of Stat6: Stat6b and Stat6c
    Patent number: 6368828
    Abstract: The present invention provides an isolated nucleic acid encoding the polypeptide Stat6b, having an amino acid sequence of Stat6 wherein a deletion in the nucleic acid is present, encompassing the last base pair of codon 39 of Stat6 and continuing through to and including codon 86 of Stat6 and an isolated polypeptide, Stat6b, having an amino acid sequence of Stat6 wherein amino acids 39-86 are deleted at the amino terminus. Also provided is an isolated nucleic acid encoding the polypeptide Stat6c, having an amino acid sequence of Stat6 wherein amino acids 537-564 are deleted and an isolated polypeptide, Stat6c, having an amino acid sequence of Stat6 wherein amino acids 537-564 are deleted. Methods of producing the polypeptide Stat6b and polypeptide Stat6c are also provided, comprising culturing cells comprising nucleic acid encoding the polypeptide Stat6b or the polypeptide Stat6c under conditions whereby the polypeptide Stat6b or the polypeptide Stat6c is produced.
    Type: Grant
    Filed: February 23, 2000
    Date of Patent: April 9, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: William LaRochelle, Bharvin K. R. Patel, Jacalyn H. Pierce
  • Immunoadhesins and methods of production and use thereof
    Patent number: 5998598
    Abstract: The invention is directed toward a compound comprising a recombinant nucleic acid encoding an immunoadhesin inserted within an adenoviral nucleic acid, wherein the recombinant nucleic acid can be packaged in an adenovirus particle and wherein expression of the recombinant nucleic acid encoding the immunoadhesin results in production of the immunoadhesin protein. The recombinant nucleic acid encoding the immunoadhesin can be within an adenovirus.
    Type: Grant
    Filed: March 10, 1997
    Date of Patent: December 7, 1999
    Assignee: The United States of America, as represented by the Department of Health and Human Services
    Inventors: Karl G. Csaky, Eddy Anglade, Daniel M. Sullivan, William LaRochelle